Emerging Therapies for the Treatment of Psoriasis [PDF]
, 2012 Psoriasis is an immune-mediated disease that affects 1%–2% of the European and North American population. While topical agents such as corticosteroids and vitamin D derivatives are prescribed for mild disease, they are generally unable to adequately ...
Alan Menter +3 more
core +1 more source
BMC Infectious Diseases, 2019 Background Ruxolitinib is a highly potent janus kinase inhibitor that places its users at risk for various bacterial infections and viral reactivation.
Katya Prakash, Douglas Richman
doaj +1 more source
Janus-kinase Inhibitors in Pathogenesis and Management of Chronic Urticaria: A Review of the Literature [PDF]
Journal of Pediatrics Review, 2023 Background: Chronic urticaria is a long-lasting condition, sometimes with serious comorbidities, severely affecting the quality of life, which makes the patients seek efficient therapies to achieve sustained remissions.
Sepideh Darougar +2 more
doaj
Janus kinase inhibitors for autoimmune disorders [PDF]
Prescriber, 2017 Three janus kinase (JAK) inhibitors ‐ baricitinib (Olumiant) and tofacitinib (Xeljanz) for rheumatoid arthritis, and ruxolitinib (Jakavi) for myelofibrosis ‐ have already been launched in the UK and others are currently being evaluated in a diverse range of autoimmune disorders and cancers.
openaire +1 more source
Experimental Pharmacological Management of Psoriasis
Journal of Experimental Pharmacology, 2021 Elena Campione,1 Terenzio Cosio,1 Monia Di Prete,2 Caterina Lanna,1 Annunziata Dattola,1 Luca Bianchi1 1Dermatologic Unit, Department of Systems Medicine, University of Rome Tor Vergata, Rome, 00133, Italy; 2Anatomic Pathology, University of Rome Tor ...
Campione E +5 more
doaj
Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor [PDF]
, 2019 The development of new systemic agents has led us into a “golden era” of management of metastatic renal cell carcinoma (RCC). Certainly, the approval of immune-checkpoint inhibitors and the combination of these with targeted compounds has irreversibly ...
Battelli, Nicola +10 more
core +3 more sources
In vivo and ex vivo regulation of visfatin production by leptin in human and murine adipose tissue : role of mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling pathways [PDF]
, 2009 Visfatin is an adipogenic adipokine with increased levels in obesity, properties common to leptin. Thus, leptin may modulate visfatin production in adipose tissue (AT).
Bee K. Tan +34 more
core +2 more sources
Targeting the Janus Kinase Family in Autoimmune Skin Diseases
Frontiers in Immunology, 2019 Autoimmune skin diseases are characterized by significant local and systemic inflammation that is largely mediated by the Janus kinase (JAK)–signal transducer and activator of transcription (STAT) pathway.
Michael D. Howell +2 more
doaj +1 more source
Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis
, 2013 This is the protocol for a review and there is no abstract. The objectives are as follows: To determine the clinical efficacy and safety of JAK1 and JAK2 inhibitors for treating MF generated by hematologic or non-hematologic conditions. © 2013 The Cochrane Collaboration.
Martí-Carvajal A.J. +3 more
openaire +2 more sources
A Targeted Quantitative Proteomic Method Revealed a Substantial Reprogramming of Kinome during Melanoma Metastasis. [PDF]
, 2020 Kinases are involved in numerous critical cell signaling processes, and dysregulation in kinase signaling is implicated in many types of human cancers.
Guo, Lei +6 more
core +1 more source